New York City Cancer Center Says Board Members Can’t Take Money from Drug and Healthcare Companies

In the wake of public backlash, a prominent New York City cancer center has announced that it is barring its top executives from serving on corporate boards of drug and healthcare companies, according to a January 11, 2019, article in the New York Times. Numerous conflicts of interests at the hospital were brought to light by reporting from the Times and ProPublica (for more information see HRC Alerts, January 9, 2019: Leaders at Prominent New York City Cancer Center Facing Internal Backlash over Industry Ties) and led to a "rippling effect," in which institutions across the country are reconsidering their financial ties, the Times said.